By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ArmaGen Technologies, Inc. 

914 Colorado Avenue

Santa Monica  California  90401  U.S.A.
Phone: 310-917-1275 Fax: 310-917-1276



Company News
ArmaGen Reports Preliminary Evidence Of Cognitive Improvement In Children With Hurler Syndrome (MPS I) Treated With AGT-181 2/17/2017 6:21:26 AM
ArmaGen CEO: Phase II Data Shows Cognitive Improvement in Juvenile Hurler Syndrome Patients 2/16/2017 11:21:41 AM
ArmaGen Technologies, Inc. Release: Company Appoints Mathias Schmidt, Ph.D., As Chief Executive Officer 1/19/2017 8:04:02 AM
ArmaGen Technologies, Inc. And Rett Syndrome Research Trust Collaborate To Develop Novel Therapeutic For The Treatment Of Rett Syndrome 7/7/2016 6:40:04 AM
ArmaGen Technologies, Inc. Announces Initiation Of Phase 2 Proof-Of-Concept Clinical Trial In Brazil To Study AGT-181 For The Treatment Of Hurler Syndrome 3/31/2016 6:09:21 AM
ArmaGen Technologies, Inc. Receives Rare Pediatric Disease Designation From FDA For AGT-181 For The Potential Treatment Of Hurler Syndrome (Mucopolysaccharidosis Type I) 11/5/2015 6:20:52 AM
ArmaGen Technologies, Inc. Announces First Patient Dosed In Phase 1/2a Clinical Trial Of AGT-181 For The Treatment Of Hurler Syndrome 9/2/2015 10:11:02 AM
ArmaGen Technologies, Inc. Achieves Clinical Milestone In Hunter Syndrome Collaboration With Shire (SHPGY) 6/15/2015 6:20:05 AM
ArmaGen Technologies, Inc. Announces FDA Acceptance Of IND Application For AGT-181 For The Treatment Of Hurler Syndrome 4/8/2015 6:15:13 AM
PacificGMP And ArmaGen Technologies, Inc. Announce Successful Manufacture Of Armagen's Investigational Enzyme Replacement Therapies, AGT-182 And AGT-181, For Phase 1 Clinical Trial 3/10/2015 6:40:25 AM